Keywords: USA, Hepatitis C treatment, Merck & Co, Roche, Victrelis, Vertex, Johnson & Johnson, Incivek, Decision Resources

Most US clinicians plan to prescribe Incivek and Victrelis for treatment-naive hep C patients

Article | 05 July 2011

Print This

More than two-thirds of surveyed US clinicians plan to prescribe Vertex/Johnson & Johnson/Mitsubishi Tanabe’s Incivek (telaprevir) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in